Skip to main content
Oncotarget logoLink to Oncotarget
. 2020 Mar 17;11(11):1006. doi: 10.18632/oncotarget.27522

Correction: Enhanced tumorigenicity by mitochondrial DNA mild mutations

Alberto Cruz-Bermúdez 1,2,3, Carmen G Vallejo 1, Ramiro J Vicente-Blanco 1,2, María Esther Gallardo 1,2,3, Miguel Ángel Fernández-Moreno 1,2,3, Miguel Quintanilla 1,4,✉, Rafael Garesse 1,2,3,✉
PMCID: PMC7082113  PMID: 32215189

This article has been corrected: The Acknowledgements section has been updated as follows:

ACKNOWLEDGMENTS

This work was supported by the “Instituto de Salud Carlos III” [PI 10/0703 and PI13/00556 to R.G and PI 04/1001 to MAFM]; “Comunidad Autónoma de Madrid” [S2010/BMD-2402 to R.G and S2010/BMD-2359 to MQ); “Fundación Mutua Madrileña” [10.04.02.0064 to MAFM], the Spanish Ministry of Economy and Competitiveness (grant SAF2013-46183-R to MQ) and FEDER funds from the E.U. to R.G. M.E.G. is a staff scientist at the Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Spain. Flow cytometry analyses were carried out at the “Servicio Interdepartamental de Investigacion” (SIdI) with the excellent technical assistance of Laura Molero Martín.

Original article: Oncotarget. 2015; 6:13628–13643. 13628-13643. https://doi.org/10.18632/oncotarget.3698


Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES